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Objectives. We sought to examine the immediate vasodilator 
effect of intracoronary estrogen on epicardial and resistance 
coronary arteries in 19 dogs. 
Background. Although estrogen reportedly dilates coronary 
arteries in vitro, the site and mechanisms of its action have not 
been fully defined in vivo. 
Methods. Epicardial coronary artery dimensions and coronary 
flow velocity were assessed using simultaneous intracoronary 
two-dimensional nd Doppler ultrasound. 
Results. Estrogen (0.1 and 1 pmol/liter) induced a significant 
increase in coronary cross-sectional rea, flow velocity and volu. 
metric blood flow. Estrogen-induced vasodilation was not influ- 
enced either by pretreatment with N%nitro-L-arginine methyl 
ester (L-NAME) (100 pmol/liter intracoronary), indomethacin 
(5 mg/kg body weight intravenously), propranolol (0.75 mg/kg 
intravenously) or the classic estrogen receptor antagonist ICI 
182,780 (10 ~mol/liter). Balloon denudation of the endothelium 
did not attenuate estrogen-induced epicardial vasodilation. Pre- 
treatment with glibenclamide (10 btmol/liter) attenuated estrogen- 
induced vasodilation only in epicardial arteries, as did verapamil 
(0.1 p~mol/liter). Estrogen had no effect on a phenylephrine 
dose-response curve in either epicardial coronary arteries or the 
microcireulation. 
Conclusions. Acute estrogen-induced ilation in canine coro- 
nary arteries is endothelium independent and is not mediated by 
the classic intracellular estrogen receptor but through non- 
genomic mechanisms, presumably at the membrane level, which 
in epicardial arteries may include effects on adenosine triphos- 
phate-sensitive potassium or calcium channels, or both. 
(J Am Coll Cardiol 1995;26:807-14) 
Animal and human studies (1,2) have demonstrated a protec- 
tive effect of estrogen on the coronary circulation. In addition 
to its beneficial effects on lipids (3), estrogen has recently been 
reported (4) to directly induce vasodilation i the coronary 
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circulation. In vitro studies (5,6) have shown that estrogen 
induces vasodilation by an endothelium-independent mecha- 
nism. However, short- and long-term estrogen treatment ap- 
pears to enhance in vivo responses to acetylcholine in the 
coronary arteries of cynomolgus monkeys (7,8). Estrogen may 
also induce vasodilation through potential effects on catechol- 
amine release (3) or inhibition of extraneuronal uptake of 
norepinephrine (uptake-2) (9) or through calcium channel 
antagonism (5,10). 
Vasodilator agents in the coronary circulation may predom- 
inantly influence ither conductance or resistance arteries (11). 
The immediate effects of estrogen administration large and 
small coronary arteries have not been adequately defined in 
vivo. The relative contributions ofendothelium-derived nitric 
oxide, modulation of alpha-adrenoceptor-mediated v socon- 
striction, blockade of extraneuronal uptake of norepinephrine 
and calcium channel antagonism have also not been examined 
in an experimental model in vivo. Further, the relation of acute 
estrogen-induced vasodilation to stimulation of classic intra- 
cellular estrogen receptors i unclear. In the present study, we 
sought to examine the acute vasodilator properties of estrogen 
in coronary conductance and resistance arteries in vivo by 
means of simultaneous intravascular two-dimensional nd 
Doppler ultrasound. Using pharmacologic antagonists ofspe- 
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cific vasodilator pathways, we examine the mechanisms of 
action of estrogen in both large and small coronary arteries. 
Methods 
Dogs. Nineteen mongrel dogs (10 male, 9 female; mean 
[_+SEM] weight 26 -+ 0.8 kg) were anesthetized with Innovar 
(0.04 mg/kg subcutaneously) and sodium pentobarbital 
(15 mg/kg intravenously), with additional doses of sodium 
pentobarbital s needed to maintain the level of anesthesia. 
Dogs were mechanically ventilated with room air. Heart rate 
was monitored by the electrocardiogram (ECG), and blood 
pressure by a cannula placed in the right internal carotid 
artery. All studies conformed to the "Position of the American 
Heart Association on Research Animal Use," adopted by the 
Association in November 1984. 
Catheterization procedures. Under fluoroscopic guidance, 
the left main coronary artery was cannulated by the transfemo- 
ral approach using an 8F canine guiding catheter (Advanced 
Cardiovascular Systems). As previously described (12), a 0.014- 
in. (0.035 cm) Doppler wire (Cardiometrics), was first intro- 
duced through the 8F guiding catheter, after which a 4.3F 
ultrasound imaging catheter (Cardiovascular Imaging Systems) 
was introduced directly over the Doppler wire into the circum- 
flex coronary artery. The Doppler transducer was positioned 
2 cm distal to the tip of the imaging catheter (11,12). 
Experimental protocols. Unless otherwise indicated, phar- 
macologic agents were administered directly into the coronary 
circulation through the guiding catheter in the ostium of the 
left main coronary artery. Measurements of coronary, artery 
cross-sectional rea and flow velocity were made at 30-s 
intervals after each administration. Intracoronary drug infu- 
sions were over a 1-min period unless otherwise specified; final 
concentrations i  the coronary artery are indicated, assuming a 
flow rate of 80 ml/min, as previously described (12,13). Except 
where other sources are stated, all drugs were obtained from 
Sigma Corp. 
Protocol I. In eight dogs (four male, four female), 17-beta- 
estradiol hemisuccinate was infused at concentrations i creas- 
ing from 10 -l° to 10 ~ mol,qiter. With each concentration, 
sufficient time was allowed for epicardial coronary dimensions 
and flow velocity to return to baseline before the next dose was 
administered. The effect of estrogen (10 7 and 10 --6 tool/liter) 
was then assessed after the following pharmacologic interven- 
tions, the order of which was randomized: l) inhibition of nitric 
oxide synthesis by intracoronary administration f N'°-nitro-~= 
arginine methyl ester (L-NAME) to obtain a final concentra- 
tion of 10 -4 mol/liter in the coronary artery (13); 2) inhibition 
of prostaglandin synthesis by intravenous infusion of 5 mg/kg 
indomethacin (Dupont-Merck) over 5 rain (previous tudies 
[14,15] have suggested that this dose is sufficient o block 
prostaglandin synthesis); 3) inhibition of adenosine triphos- 
phate (ATP)-sensitive potassium channels by intracoronary 
infusion of glibenclamide (10 s tool/liter). A washout period 
of at least 45 rain was allowed between the administration f 
antagonists. Finally, balloon denudation ofthe coronary endo- 
thelium was performed using a percutaneous balloon angio- 
plasty catheter of appropriate size (2.0 to 3.5 ram), as judged 
from the angiogram. The balloon was inflated to 4 to 6 atm, 
and withdrawn while inflated, and this procedure was repeated 
three times. We previously showed (16) that this protocol 
virtually abolished acetylcholine-induced vasorelaxation. 
Protocol 2. In the next six dogs (three male, three female), 
the effect of estrogen on alpha-adrenoceptor function was 
examined by infusing intracoronary phenylephrine (10 -l° to 
10 _7 tool/liter), before and after a 5-rain infusion of estrogen 
(10 _6 mol/liter). Subsequently, after a 45-rain washout period, 
interaction with calcium channels was examined by assessing 
the response to estrogen (10 7 and 10 -6 tool/liter) before and 
after infusion of intracoronary verapamil (10 -7 mol/liter). 
Preliminary experiments showed that higher doses of vera- 
pamil (10 6 and 10 -5 mol/liter) were not well tolerated and 
resulted in profound bradycardia nd hypotension. Trans- 
venous atrial pacing did not prevent hypotension at these 
higher doses of verapamil. 
Protocol 3. In the remaining five dogs (three male, two 
female), the effect of estrogen (10 7 and 10 -6 mol/liter) was 
examined after blockade of classical estrogen receptors with 
10 gmol/litcr ICI 182,780 (17). Finally, because strogen may 
block extraneuronal norepinephrine r uptake, and the result- 
ing increase in local norepinephrine concentrations may acti- 
vate coronary beta-adrenoceptors, thevasodilator effect of 
estrogen was examined before and after intravenous beta- 
adrenoceptor blockade with propranolol (Solo-Pak Laborato- 
ries), 0.75 mg/kg body weight (18). Transvenous atrial pacing at 
a rate of 130 beats/rain was used during beta-blockade to 
prevent he decrease in heart rate and blood pressure. As in 
protocol , a period of at least 45 rain was allowed between 
administration f pharmacologic antagonists. 
Two-dimensional u trasound system description and image 
analysis. The ultrasound catheter (4.3F) had a fixed 30-MHz 
transducer and a rotating mirror assembly. Images were dis- 
played on a video monitor; axial resolution was -150 t~m and 
lateral resolution -250 t~m. Gain, contrast and reject settings 
were adjusted by the operator to yield a well balanced gray- 
scale appearance on the video display. Real-time images were 
stored on high quality super-VHS videotape for subsequent 
off-line analysis. As previously described (11,12), selected 
portions of the videotape were digitized (12 bits, Rasterops 
324) in real time (30 frames/s) and stored on a computer disk 
for off-line determination f lumen area. 
Doppler ultrasound system description. Doppler-derived 
blood flow velocities were measured using a 0.014-in. 
(0.035 cm) steerable Doppler guide wire (FloWire, Cardiomet- 
tics). This guide wire system has a miniature Doppler ultra- 
sound crystal that transmits ignals at a carrier frequency of 
15 MHz and receives pulsed wave ultrasound signals, sampled 
at a distance of 5 mm from the guide wire tip. The Doppler 
signals are analyzed by a FloMap instrument (Cardiometrics) 
in which dedicated igital signal processing chips perform the 
fast Fourier transformation required for the spectral display. 
The signals are transformed into a gray scale, and the resultant 
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Table 1. Epicardial Coronary Cross-Sectional Area, Average Coronary Peak Flow Velocity and Volumetric Coronary Blood Flow at Baseline 
and in Response to Estrogen Before and After Administration f Pharmacologic Antagonists 
Baseline Estrogen (0.1 ,~mol/liter) Estrogen (1 tzmol/liter) 
CSA APV CBF CSA APV CBF CSA APV CBF 
(mm 2) (era/s) (ml/min) (ram 2) (era/s) (ml/min) (mm 2) (cm/s) (ml/min) 
Rest values and initial response 10.9 _+ 1.1 23.0 ± 3.8 69.7 ± 8.2 11.5 ± 1.1 27.8 ± 4.6 87.9 ± 9.1 11.8 _+ 1.1 29.9 _+ 4.3 98.4 _+ 10.3 
Before L-NAME 10.9 _+ 1.0 22.5 ± 3.1 66.0 _+ 7.9 See initial response 
After L-NAME 10.4 ± 1.0 22.6 _+ 3.6 65.6 _+ 6.5 11.0 _+ 1.1 26.9 _+ 3.8 88.6 _+ 8.7 11.4 ± 1.2 29.5 ± 4.0 95.2 + 9.7 
Before indomethacin 10.9 ± 1.0 22.0 _+ 3.1 65.3 ± 7.5 See initial response 
After indomethacin 10.8 _+ 1.1 21.0 _+ 3.6 62.4 : 6.6 11.4 ± 1.1 26.9 _+ 3.9 91.8 _+ 9.9 11.6 ± 1.1 28.7 _+ 4.6 91.7 _+ 10.6 
Before glibenclamide 10.8 _+ 1.1 20.6 _+ 3.5 63.8 -- 6.5 See initial response 
After glihenclamide 10.4 _+ 1.2 20.5 ± 4.0 58.1 ± 5.9 10.8 ± 1.1 24.1 _+ 3.8 78.1 ± 8.7 10.9 _~ 1.3 26.7 _+ 4.4 83.6 ± 8.9 
Before verapamil 10.8 ± 0.7 22.0 _+ 2.0 71.3 _+ 9.9 11.4 _+ 1.0 26.8 _+ 4.2 89.0 _+ 9.1 11.7 _+ 0.9 28.9 ± 3.9 99.6 _+ 9.3 
After verapamil 10.5 + 1.0 20.5 _+ 4.2 58.7 ± 12 10.9 _+ 0.9 25.8 ± 3.1 83.0 + 8.7 10.9 _+ 1.0 26.7 ± 4.5 83.9 _+ 11.6 
Before propranolol 8.9 _+ 0.8 20.3 + 5.1 55.0 _+ 14 9.4 _+ 0.9 27.0 _+ 4.0 76.0 + 9.9 9.9 2 1.0 28.5 _+ 8.3 84.8 _+ 12.4 
After propranolol 8.3 + 0.7 21 + 6.3 52.7 + 11 8.9 _+ 0.8 26.0 ± 3.5 70.1 2 8.9 9.3 _+ 0.8 27.8 _+ 5.2 76.8 +_ 15.0 
Before ICI 182,780 8.9 ± 0.9 20.1 : 4.0 54.1 _+ 11 See pre-propranolol values 
After ICI 182,780 9.0 _+ 0.8 19 ± 4.1 51.9 ± 12 9.5 _+ 0.8 23.0 _+ 5.0 66.6 _+ 10 10.1 _+ 0.9 24.3 _+ 4.4 72.7 ± 12.9 
Data presented are mean value ± SEM. APV - average coronary peak flow velocity; CBF = volumetric oronary blood flow; CSA = epicardial coronary 
cross-sectional area; L-NAME = N~-nitro-L-arginine methyl ester. 
spectrum displayed on a monitor. In our study, the ECG and 
arterial pressure waveform were simultaneously displayed on 
the monitor. Also displayed were quantitative measurements 
of average peak velocity throughout the cardiac cycle. The 
monitor display was continuously recorded on VHS videotape 
for further off-line analysis and comparison with corresponding 
cross-sectional u trasound images. 
Calculations and statistical analysis. Lumen cross- 
sectional area (CSA) at baseline and after administration of
drugs was determined by computer-assisted planimetry. Volu- 
metric coronary blood flow (CBF) was calculated from the 
relation CBF = CSA × APV × 0.5, as previously validated 
(19), where APV is average peak velocity. Dose-response 
relations with estrogen were analyzed by analysis of variance 
for repeated measures, followed by a post hoc Student- 
Neuman-Keuls test. The effects of phenylephrine b fore and 
after estrogen were compared by a two-way repeated measures 
analysis of variance. The effects of L-NAME, indomethacin, 
glibenclamide, verapamil, ICI 182,780 and propranolol on 
estrogen-induced vasodilation were analyzed by the Student t 
test for paired observations. Results are expressed as mean 
value + SEM. 
Resu l ts  
Rest coronary dimensions and flow. Mean heart rate at 
rest was 124 _+ 6 beats/min, and mean arterial pressure was 
96 _+ 5 mm Hg. Mean values for rest coronary cross-sectional 
area, average peak velocity and volumetric coronary blood flow 
are shown in Table 1. 
Effect of 17-beta-estradiol on coronary artery dimensions 
and flow. At the 10 -7 and 10 -6 mol/liter concentrations, 
17-beta-estradiol caused an increase in coronary cross- 
sectional area, average peak velocity and volumetric coronary 
blood flow (Fig. 1, Table 1). The magnitude of the vasodilator 
effect was similar in male and female dogs. The peak effect was 
seen between 90 and 120 s, and the mean duration of the 
vasodilator response was 4.1 + 0.8 rain. No significant changes 
in systemic arterial pressure or heart rate were observed with 
any dose. 
Effect of L-NAME on 17-beta-estradiol-induced coronary 
vasodilation. Baseline cross-sectional rea was reduced by 
L-NAME (p = 0.003), but average peak velocity and volumet- 
ric blood flow remained unchanged. Blood pressure (99 + 
4 mm Hg) and heart rate (122 _+ 5 beats/rain) remained 
unchanged with L-NAME. At both the 10 7 and 10 -6 tool/liter 
concentrations of estrogen, the magnitude of estrogen-induced 
increase in cross-sectional rea, average peak velocity and 
coronary blood flow were also unchanged by L-NAME (Fig. 2, 
Table 1). 
Effect of indomethacin on 17.beta-estradiol-induced coro. 
nary vasodilation. Baseline cross-sectional area, average peak 
velocity and coronary blood flow remained unchanged with 
indomethacin. Blood pressure (94 _+ 6 mm Hg) and heart rate 
(125 + 4 beats/rain) remained unchanged with indomethacin. 
At both the 10 7 and 10 -6 tool/liter concentrations of estro- 
gen, the magnitude of estrogen-induced increase in cross- 
sectional area, average peak velocity and coronary blood flow 
were also unchanged by indomethacin (Fig. 2, Table 1). 
Effect of glibenclamide on 17-beta-estradiol-induced coro- 
nary vasodilation. After infusion of glibenclamide, there was a 
significant reduction in coronary artery cross-sectional rea 
(p = 0.05) but not in average peak velocity or coronary blood 
flow velocity (Table 1). Blood pressure (98 __+ 6 mm Hg) and 
heart rate (123 _+ 7 beats/min) remained unchanged with 
glibenclamide. However, at the 10 -6 mol/liter concentration f 
estrogen, the magnitude of the increase in epicardial coronary 
cross-sectional area was attenuated by glibenclamide (10.4 + 
1.2 to 10.9 _-2- 1.3 mm2), although estrogen-induced increases in
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Figure 1. Effect of increasing concentrations of estrogen on coronary 
cross-sectional area (CSA) (top), Doppler-derived average peak veloc- 
ity (APV) (middle) and calculated coronary.' blood flow (CBF) (bot- 
tom). Average error bars represent the average standard error of the 
mean from analysis of variance (ANOVA), calculated as (mean square 
error [obtained from ANOVA table] number of dogs) t~5. *Significant 
reduction at p < 0.05. 
blood flow velocity and volumetric blood flow remained un- 
changed after glibenclamide administration (Fig. 3, Table l). 
Effect of verapamil on estrogen-induced vasodilation. In- 
tracoronary verapamil reduced mean arterial pressure from 
98 _+ 3 to 89 _+ 5 mm Hg (p = 0.06) and heart rate from 120 _+ 
10 to 99 + 4 beats/min (p < 0.02). Coronary, artery cross- 
sectional area was unchanged by verapamil, as was average 
peak velocity. The vasodilator response to estrogen at 
10 -6 tool/liter was attenuated in the epicardial coronary arter- 
ies (p < 0.05) but unchanged in the coronary microcirculation 
(Fig. 3, Table 1). 
Effect of estrogen on phenylephrine-induced coronary va- 
soconstriction, lntracoronary phenylephrine caused a dose- 
dependent decrease in both coronary cross-sectional rea and 
average peak velocity. However, at doses < 1 txmol/liter, there 
was no change in either blood pressure or heart rate. The 
vasoconstrictor response to phenylephrine was not altered by 
an infusion of intracoronary estrogen, either in the epicardial 
coronary circulation or in the resistance arteries (Fig. 4). 
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Figure 2. Estrogcn-induced increase in cross-sectional rea (CSA), 
average peak velocity (APV) and calculated coronary blood flow 
(CBF) before and after administration of (top) N'%nitro-L-arginine 
methyl ester (c-NAME, 100 ~,mol/liter), showing no change in estrogen- 
induced coronary vasodilation induced by L-NAME, and (bottom) 
indomethacin (5mg/kg intravenously), showing no change in estrogen- 
induced coronau vasodilation induced by indomethaein. 
Effect of ICI 182,780 on estrogen-induced coronary vasodi- 
lation. The selective strogen receptor antagonist ICI 182,780 
(10 /,mol/liter) caused no change in either coronary cross- 
sectional area, average peak velocity or coronary blood flow. 
Blood pressure (99 -+ 4 mm Hg) and heart rate (122 _+ 
5 beats/rain) remained unchanged with ICI 182,780. The 
increase in coronary, cross-sectional rea induced by estrogen 
at 10 -7 and 10 -6 tool/liter was not altered by ICI 182,780, nor 
was the estrogen-induced increase in flow velocity or volumet- 
ric blood flow (Fig. 5, Table 1). 
Effect of propranolol on estrogen-induced coronary vasodi- 
lation. There was a small decrease in baseline cross-sectional 
area induced by intravenous propranolol but no significant 
change in coronary blood flow velocity. However, at both the 
10 7 and 10 6 tool/liter concentrations of estrogen, the mag- 
nitude of estrogen-induced increase in cross-sectional rea, 
average peak velocity and coronary blood flow were not altered 
by pretreatment with propranolol (Fig. 5, Table 1). 
Effect of ethanol (vehicle) on coronary arteries. Intracoro- 
nary ethanol, administered in a concentration equivalent o 
that accompanying estrogen at 1 tzmol/liter (0.01%) did not 
induce any change in either coronary cross-sectional area 
(10.7 +_ 1.1 mm 2 before and 10.9 +_ 1.1 mm 2 after ethanol, p = 
NS) or in average peak velocity (23.0 _+ 3.8 cm/s before and 
23.5 +_ 4.1 cm/s after ethanol, p = NS). 
Effect of balloon denudation on 17-beta-estradiol-indueed 
vasodilation. After balloon denudation of the endothelium, 
lumen area increased by 7%. However, the magnitude of 
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Figure 3. Estrogen-induced increase in cross-sectional rea (CSA), 
average peak velocity (APV) and calculated coronary blood flow 
(CBF) before and after administration of (top) glibenclamide (10 
/xmol/liter), showing an attenuation in estrogen-induced picardial 
coronary vasodilation but no change in estrogen-induced increase in 
average peak velocity induced by, glibenclamide, and (bottom) intra- 
coronary, verapamil (0.1 p.mol/liter), showing an attenuation i  estrogen- 
induced epicardial corona~, vasodilation but no change in estrogen- 
induced increase in average peak velocity induced by verapamil. 
*Significant reduction at p < 0.05 (before vs. after glibenclamide or
verapamil). 
estrogen-induced increase in cross-sectional rea was un- 
changed after balloon denudation (Fig. 6). 
Discussion 
The present study was designed to examine the mechanisms 
of acute estrogen-induced vasodilation in the canine coronary 
circulation in vivo. We found that estrogen causes immediate 
dilation of both conductance and resistance coronary arteries 
at concentrations ->0.1 txmol/liter. In the epicardial coronary 
circulation, estrogen-induced vasodilation was partially but 
significantly attenuated by blockade of ATP-sensitive potas- 
sium channels, as demonstrated bythe action of glibenclamide, 
and by calcium channel blockade, as demonstrated by the 
action of verapamil. However, estrogen-induced vasodilation 
was not attenuated by either I_-NAME or indomethacin, 
suggesting that its effect is not mediated by nitric oxide or 
prostaglandin release either in the epicardial circulation or 
microcirculation. The lack of effect of propranolol and ICI 
182,780 on estrogen-induced conductance and resistance ves- 
sel dilation suggests that this effect of estrogen is not mediated 
by beta-adrenoceptors r classical intracellular estrogen recep- 
tors, respectively. Balloon denudation of the endothelium of 
the epicardial coronary arterxl also failed to influence strogen- 
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Figure 4. Effect of pretreatment with estrogen (1 p, mol/liter) on 
phenylephrine-induced d creases in cross-sectional area (CSA) (top); 
average peak velocity (APV) (middle); and calculated coronary blood 
flow (CBF) (bottom). There was no shift in the phenylephrine dose- 
response curves after estrogen. Average rror bars as in Figure 1. 
induced vasodilation, suggesting that the effect is largely 
endothelium independent. 
Mechanisms of estrogen-induced coronary vasodilation. 
Role of the endothelium Animal and human studies (1,2) have 
demonstrated a protective ffect of estrogen therapy on coro- 
nary artery disease. In vitro studies (5,6) have shown that 
17-beta-estradiol re axes coronary arteries and have suggested 
that this may occur by an endothelium-independent mecha- 
nism. However, estradiol has been reported (20) to modulate 
endothelium-dependent r sponses of vascular ings from rab- 
bit femoral arteries. Hayashi et al. (21) could not show any 
differences in the responsiveness of aortic rings from male and 
female rabbits to endothelium-dependent a d endothelium- 
independent vasodilators but demonstrated that basal release 
of nitric oxide is greater in rings from female rabbits. 
Estradiol is reported (22) to cause an increase in prosta- 
glandin biosynthesis in rat aortic smooth muscle cells. How- 
ever, in vitro studies (5) in the rabbit coronary artery have 
suggested that estrogen-induced vasorelaxation is not influ- 
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Figure 5. Estrogen-induced increase in cross-sectional area (CSA), 
average peak veloci~' (APV) and calculated coronary blood flow 
(CBF) (top) before and after administration f the classic estrogen 
receptor antagonist ICI 182,780 (10 gmol/liter), showing no change in
estrogen-induced oronary vasodilation i duced by ICI 182,780, and 
(bottom) propranolol (0.75 mg/kg intravenously), showing no change 
in estrogen-induced oronary vasodilation induced by propranolol. 
enced by inhibitors of prostanoid release. Preliminary studies 
examining the effect of estrogen on expression of nitric oxide 
synthase in endothelial cells are conflicting, with one study (23) 
showing an enhancement and another (24) showing no change. 
Our in vivo studies how no effect of L-NAME or indomethacin 
on estrogen-induced vasodilation in either large or small 
coronary arteries. Importantly, mechanical denudation of the 
endothelium had no effect on the vasodilator response, sug- 
gesting that it is unlikely that the endothefium contributes 
significantly to short-term estrogen-induced picardial coro- 
nary vasodilation. 
Calcium channel antagonism. Previous in vitro studies in 
uterine arterial smooth muscle (10) and in the rabbit corona~, 
artery (5) have suggested that estrogens have calcium- 
antagonistic properties. In the present study, the coronary 
vasodilator effect of estrogen i  the epicardial coronary after' 
was attenuated bypretreatment with verapamil (although at a 
low concentration f calcium channel antagonist), suggesting 
that estrogen-induced vasodilation in conductance arteries 
may in part be through calcium channel antagonism. Although 
rest epicardial coronary cross-sectional rea and blood flow 
velocity appeared to be unchanged by verapamil, this was in 
the presence of a significant decrease in blood pressure and 
heart rate. A direct vasodilator effect of verapamil on the large 
and small coronary arteries may thus have been masked by the 
hemodynamic changes observed. 
Role of ATP-sensitive potassium channels. In addition, 
estrogen-induced picardial coronarx, vasodilation was attenu- 
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Figure 6. Estrogen-induced increases in cross-sectional area (CSA) 
before and after balloon denudation f the endothelium in an epicar- 
dial coronary artery, showing no change in the magnitude of the 
vasodilator effect of estrogen after balloon denudation. 
ated in part by pretreatment with glibenclamide, which blocks 
ATP-sensitive potassium channels. The significance of this 
finding is unclear: It may suggest that estrogen i fluences these 
potassium channels on vascular smooth muscle. Glibenclamide 
caused a vasoconstrictor response in epicardial coronary arter- 
ies, suggesting that ATP-sensitive potassium channels may play 
a role in basal vascular tone. However, this change in tone does 
not explain its effect on estrogen-induced vasodilation because 
L-NAME also increased vascular tone in the epicardial coro- 
nary arteries but did not inhibit estrogen-induced vasodilation. 
Recent studies (25) have suggested that glibenclamide r verses 
the pinacidil- and cromokalim-induced opening of calcium- 
activated potassium channels. If estrogen acts through these 
channels, attenuation ofestrogen-induced picardial vasodila- 
tion by both glibenclamide and verapamil could be explained 
as follows: Calcium entry blockade would diminish the avail- 
able intraccllular calcium required to activate the calcium- 
activated potassium channels. 
Nongenomic versus genomic effects'. The current study dem- 
onstrates that the vasodilator effect of estrogen isobserved in 
corona~ conductance and resistance vessels at similar doses. 
Other coronary, vasodilator agents have been shown to have 
differential effects on large and small coronary arteries; for 
instance, nitroglycerin has been shown to predominantly bea 
dilator of conductance vessels, whereas adenosine mainly 
dilates resistance arteries (11). However, the immediate vaso- 
dilator effect of estrogen was only observed at doses 
-0.1 tzmol/liter, whereas physiologic levels of estrogen i  the 
plasma are within 100 to 500 pmol/liter in the follicular phase 
of the cycle, increasing from 500 to 1300 pmol/liter in the 
midcycle phase (26). This effect was also short-lived, suggesting 
that it is a nongenomic response. We do not know whether 
more long-term administration of estrogen might result in 
coronary vasodilation at lower concentrations, or whether 
genomic effects might be seen in this situation. 
Steroids are generally considered as hormones acting 
through genomic processes involving transcription, translation 
and, subsequently, protein synthesis. Steroid-related responses 
are characterized bya latency of 1 to 2 h, and the supeffamily 
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of intracellular receptors mediating these responses have been 
cloned (27). However, a nongenomic pathway of steroid action 
has recently been suggested by the demonstration of estrogen- 
binding sites in plasma membranes from endometrial and 
anterior pituitary cells (28,29). These binding sites could 
represent the receptors transmitting rapid effects of estrogens, 
which also have been described as early responses in various 
cell systems (30-33). Recently, aldosterone membrane recep- 
tors distinctly different from the classic intracellular receptors 
(34-36) have been demonstrated. Thus, a two-step model for 
sequential nongenomic and genomic steroid hormone action is 
becoming increasingly accepted (37,38). In the present study, 
the classic intracellular estrogen-receptor antagonist IC1 
182,780 did not significantly inhibit estrogen-induced vasodila- 
tion in either conductance or resistance arteries. This finding 
confirms previous in vitro observations in rings from the rabbit 
aorta and coronary arteries: In those studies, ICI 182,780 did 
not block, diminish or delay the relaxation effect of 17-beta- 
estradiol (5). Thus, it appears that the vasodilator effect of 
estrogen is likely to represent a direct, nongenomic effect 
possibly transmitted through membrane receptors different 
from the classic intracellular estrogen receptors. 
Interaction with adrenoceptors. Because strogen may block 
extraneuronal norepinephrine r uptake (9), and the resulting 
increase in local norepinephrine concentrations may activate 
coronary beta-adrenoceptors, thevasodilator effect of estrogen 
was examined before and after intravenous beta-adrenoceptor 
blockade with propranolol. However, pretreatment with pro- 
pranolol did not attenuate the vasodilator effect of estrogen on 
either the epicardial or microvascular coronary circulation. 
Thus, stimulation of beta-adrenoceptors in the coronary circu- 
lation as a mechanism of estrogen-induced vasodilation ap- 
pears unlikely. Previous studies (39) have suggested that 
estrogen-induced increases in uterine blood flow may result in 
part from alterations in alphal-adrenoceptor numbers. In the 
present study, however, acute estrogen administration did not 
appear to influence the response to alphal-adrenoceptor stim- 
ulation, suggesting that the inhibition of alphat-adrenoceptor 
activity does not play a role in the acute coronary vasodilator 
response. 
Study limitations. In view of the increase in coronary 
blood flow after estrogen administration, it is possible that the 
estrogen-induced dilation of epicardial coronary arteries was 
due to flow-mediated endothelium-dependent vasodilation. 
However, in the present study, there was no attenuation of the 
estrogen-induced vasodilation after I,-NAME administration: 
Flow- and shear stress-mediated vasodilation in epicardial 
coronary arteries is endothelium dependent (40) and would 
have been attenuated by the nitric oxide synthase inhibitor. 
Thus, it is unlikely that the dilation of the proximal epicardial 
arteries observed in the present study was due to endothelium- 
dependent flow-mediated vasodilation. Although the present 
study suggests that the mechanism of acute estrogen-induced 
vasodilation may be related to blockade of calcium channels on 
activation of potassium channels, or both. other potential 
mechanisms, uch as the role of protein kinase C (41), need to 
be studied. 
The measurement of absolute coronary blood flow using 
combined two-dimensional nd Doppler ultrasound may have 
some inaccuracy inherent in the technique (19). However, all 
of our inferences are based on within-animal comparisons and 
paired data, and the final emphasis is on change from baseline 
rather than on absolute values. Therefore, it is unlikely that the 
interpretation of our data was influenced by the measurement 
technique. It is also possible that coronary blood flow was 
decreased by the presence of the imaging catheter in the 
coronary artery. However, we used a 4.3F imaging catheter 
with a diameter of -1.37 ram, which occupies an area of 
1.47 mm 2. This would cause a percent area stenosis of 13.4% in 
an artery with a cross-sectional rea of 11 mm 2, an obstruction 
unlikely to cause a major restriction to flow. 
Finally, although our findings of an acute vasodilator effect 
of high doses of estrogen in large and small coronary arteries 
may have potential clinical implications in the treatment of 
angina and myocardial ischemia, studies of long-term admin- 
istration of estrogen in physiologic doses are required to 
elucidate its cardioprotective properties. 
Conclusions. Supraphysiologic doses of estrogen appear to 
cause dilation of conductance and resistance coronary arteries 
in dogs when administered acutely into the coronary circula- 
tion. The mechanism of this vasodilation is endothelium 
independent and appears to be mediated not by the classical 
intracellular estrogen receptor but through nongenomic mech- 
anisms, presumably at the membrane l vel, which in epicardial 
arteries may include effects on ATP-sensitive potassium or 
calcium channels, or both. The relation of our findings to the 
cardioprotective effect of estrogen is unclear. Further studies 
are needed to confirm the long-term effects of estrogen 
administration i vivo. 
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